Art

J-GLOBAL ID：200902208506336998   Reference number：06A0372037

Guidelines for the proper use of etanercept in Japan

日本におけるエタネルセプトの適正使用ガイドライン

Author (3)： MIYASAKA Nobuyuki (Tokyo Medical and Dental Univ., Tokyo, JPN) ,  TAKEUCHI Tsutomu (Saitama Medical Univ., Saitama, JPN) ,  EGUCHI Katsumi (Nagasaki Univ., Nagasaki, JPN)
Material： Modern Rheumatology  (Mod Rheumatol)
Volume： 16  Issue： 2  Page： 63-67  Publication year： 2006 
JST Material Number： L5142A  ISSN： 1439-7595  Document type： Article
Article type： 解説  Country of issue： United Kingdom (GBR)  Language： ENGLISH (EN)

Thesaurus term： antirheumatic drug ,...
Semi thesaurus term： *rheumatoid arthritis ,...

   To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=06A0372037&from=J-GLOBAL&jstjournalNo=L5142A") }}

JST classification (1)： Drug therapy(=pharmacotherapy)for musculoskeletal diseases  (GG05020D)

Reference (18)：

• MORELAND, KW. Etanercept therapy in rheumatoid arthritis. A randomised, controlled trial. Ann Intern Med. 1999, 130, 478
• WEINBLATT, ME. A trial of etanercept, a recombinant human tumor necrosis factor : Fc fusion protein in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med. 1999, 340, 253
• BATHON, JM. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med. 2000, 343, 1586-1593
• KLARESKOG, L. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis : double-blind randomized controlled trial. Lancet. 2004, 363, 675-681
• KEANE, J. Tuberculosis associated with infliximab, a tumor necrosis factor α-neutralizing agents. N Engl J Med. 2001, 345, 1098-1104

Terms in the title (4)： 日本 ,  エタネルセプト ,  適正使用 ,  ガイドライン